Literature DB >> 26635036

Twenty years of the Italian Fanconi Anemia Registry: where we stand and what remains to be learned.

Antonio M Risitano1, Serena Marotta1, Rita Calzone2, Francesco Grimaldi1, Adriana Zatterale3.   

Abstract

The natural history of Fanconi anemia remains hard to establish because of its rarity and its heterogeneous clinical presentation; since 1994, the Italian Fanconi Anemia Registry has collected clinical, epidemiological and genetic data of Italian Fanconi Anemia patients. This registry includes 180 patients with a confirmed diagnosis of Fanconi anemia who have either been enrolled prospectively, at diagnosis, or later on. After enrollment, follow-up data were periodically collected to assess the clinical course, possible complications and long-term survival; the median follow up was 15.6 years. The main goal of the study was to describe the natural history of Fanconi anemia, focusing on the following variables: family history, disease presentation, development of hematological manifestations, development of malignancies, occurrence of hematopoietic stem cell transplantation and survival. Typical morphological and/or hematological abnormalities and/or growth retardation were the most common manifestations at diagnosis; the majority of patients (77%) exhibited hematological abnormalities at the initial presentation, and almost all (96%) eventually developed hematological manifestations. More than half of the patients (57%) underwent a bone-marrow transplant. The occurrence of cancer was quite rare at diagnosis, whereas the cumulative incidence of malignancies at 10, 20 and 30 years was 5%, 8% and 22%, respectively, for hematological cancers and 1%, 15% and 32%, respectively, for solid tumors. Overall survival at 10, 20 and 30 years were 88%, 56% and 37%, respectively; the main causes of death were cancer, complications of the hematological presentation and complications of transplantation. These data clearly confirm the detrimental outcome of Fanconi anemia, with no major improvement in the past decades. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Year:  2015        PMID: 26635036      PMCID: PMC4815723          DOI: 10.3324/haematol.2015.133520

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  31 in total

1.  Stem cell transplantation from HLA-matched related donor for Fanconi's anaemia: a retrospective review of the multicentric Italian experience on behalf of AIEOP-GITMO.

Authors:  C Dufour; R Rondelli; F Locatelli; M Miano; G Di Girolamo; A Bacigalupo; C Messina; F Porta; A Balduzzi; A P Iorio; E Buket; E Madon; A Pession; G Dini; P Di Bartolomeo
Journal:  Br J Haematol       Date:  2001-03       Impact factor: 6.998

2.  [The Italian Fanconi Anemia Registry].

Authors:  A Zatterale; R Calzone; E Montone; G Pagano
Journal:  Ann Ist Super Sanita       Date:  1999       Impact factor: 1.663

3.  A high susceptibility of Fanconi's anemia to chromosome breakage by DNA cross-linking agents.

Authors:  M S Sasaki; A Tonomura
Journal:  Cancer Res       Date:  1973-08       Impact factor: 12.701

4.  First announcement of the Fanconi anemia International Registry.

Authors:  A D Auerbach; T M Schroeder
Journal:  Blood       Date:  1982-10       Impact factor: 22.113

5.  [Spontaneous chromosome aberrations in familial panmyelopathy].

Authors:  T M Schroeder; F Anschütz; A Knopp
Journal:  Humangenetik       Date:  1964

6.  The use of haematopoietic stem cell transplantation in Fanconi anaemia patients: a survey of decision making among families in the US and Canada.

Authors:  Sadie P Hutson; Paul K J Han; Jada G Hamilton; Sean C Rife; Mohamad M Al-Rahawan; Richard P Moser; Seth P Duty; Sheeba Anand; Blanche P Alter
Journal:  Health Expect       Date:  2013-04-29       Impact factor: 3.377

7.  Individualized risks of first adverse events in patients with Fanconi anemia.

Authors:  Philip S Rosenberg; Yi Huang; Blanche P Alter
Journal:  Blood       Date:  2004-04-01       Impact factor: 22.113

Review 8.  Cancer in Fanconi anemia, 1927-2001.

Authors:  Blanche P Alter
Journal:  Cancer       Date:  2003-01-15       Impact factor: 6.860

9.  A 20-year perspective on the International Fanconi Anemia Registry (IFAR).

Authors:  David I Kutler; Bhuvanesh Singh; Jaya Satagopan; Sat Dev Batish; Marianne Berwick; Philip F Giampietro; Helmut Hanenberg; Arleen D Auerbach
Journal:  Blood       Date:  2002-09-26       Impact factor: 22.113

10.  Cancer incidence in persons with Fanconi anemia.

Authors:  Philip S Rosenberg; Mark H Greene; Blanche P Alter
Journal:  Blood       Date:  2002-09-05       Impact factor: 22.113

View more
  14 in total

Review 1.  Hematopoietic cell transplantation in Fanconi anemia: current evidence, challenges and recommendations.

Authors:  Christen L Ebens; Margaret L MacMillan; John E Wagner
Journal:  Expert Rev Hematol       Date:  2016-12-21       Impact factor: 2.929

Review 2.  Understanding the cellular origin and progression of esophageal cancer using esophageal organoids.

Authors:  Uma M Sachdeva; Masataka Shimonosono; Samuel Flashner; Ricardo Cruz-Acuña; Joel T Gabre; Hiroshi Nakagawa
Journal:  Cancer Lett       Date:  2021-04-07       Impact factor: 9.756

3.  Dearth and Delayed Maturation of Testicular Germ Cells in Fanconi Anemia E Mutant Male Mice.

Authors:  Chun Fu; Khurshida Begum; Philip W Jordan; Yan He; Paul A Overbeek
Journal:  PLoS One       Date:  2016-08-03       Impact factor: 3.240

4.  Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population.

Authors:  Orna Steinberg-Shemer; Tracie A Goldberg; Joanne Yacobovich; Carina Levin; Ariel Koren; Shoshana Revel-Vilk; Tal Ben-Ami; Amir A Kuperman; Vered Shkalim Zemer; Amos Toren; Joseph Kapelushnik; Ayelet Ben-Barak; Hagit Miskin; Tanya Krasnov; Sharon Noy-Lotan; Orly Dgany; Hannah Tamary
Journal:  Haematologica       Date:  2019-09-26       Impact factor: 9.941

Review 5.  Nonsense Suppression Therapy: New Hypothesis for the Treatment of Inherited Bone Marrow Failure Syndromes.

Authors:  Valentino Bezzerri; Martina Api; Marisole Allegri; Benedetta Fabrizzi; Seth J Corey; Marco Cipolli
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

6.  Natural Killer Cell Degranulation Defect: A Cause for Impaired NK-Cell Cytotoxicity and Hyperinflammation in Fanconi Anemia Patients.

Authors:  Snehal Shabrish; Madhura Kelkar; Niranjan Chavan; Mukesh Desai; Umair Bargir; Maya Gupta; Priti Mehta; Akanksha Chichra; Chandrakala S; Prasad Taur; Vinay Saxena; Babu Rao Vundinti; Manisha Madkaikar
Journal:  Front Immunol       Date:  2019-03-21       Impact factor: 7.561

7.  Fatal Myelotoxicity Following Palliative Chemotherapy With Cisplatin and Gemcitabine in a Patient With Stage IV Cholangiocarcinoma Linked to Post Mortem Diagnosis of Fanconi Anemia.

Authors:  Nils W Engel; Simon Schliffke; Ulrich Schüller; Christian Frenzel; Carsten Bokemeyer; Christian Kubisch; Davor Lessel
Journal:  Front Oncol       Date:  2019-05-22       Impact factor: 6.244

8.  Generating New FANCA-Deficient HNSCC Cell Lines by Genomic Editing Recapitulates the Cellular Phenotypes of Fanconi Anemia.

Authors:  Ricardo Errazquin; Esther Sieiro; Pilar Moreno; María José Ramirez; Corina Lorz; Jorge Peral; Jessica Ortiz; José Antonio Casado; Francisco J Roman-Rodriguez; Helmut Hanenberg; Paula Río; Jordi Surralles; Carmen Segrelles; Ramon Garcia-Escudero
Journal:  Genes (Basel)       Date:  2021-04-09       Impact factor: 4.096

9.  Oral Tongue Cancer in a Patient with Fanconi Anemia: A Case Report and Literature Review.

Authors:  Siyao Deng; Wenjing Ye; Shichuan Zhang; Guiquan Zhu; Peng Zhang; Yanqiong Song; Fanglei Duan; Jinyi Lang; Shun Lu
Journal:  Cancer Manag Res       Date:  2021-04-12       Impact factor: 3.989

10.  Graves' orbitopathy after allogeneic bone marrow transplantation in a patient with Fanconi anemia - side effect of alemtuzumab therapy?

Authors:  Luminita Nicoleta Cima; Ioana Maria Lambrescu; Lavinia Stejereanu; Anca Colita; Reuven Or; Simona Fica
Journal:  Clin Case Rep       Date:  2018-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.